Navigation Links
Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
Date:9/21/2007

o osteoporosis product candidates in pre-clinical studies. For further information regarding Biodel, please visit the Company's website at http://www.biodel.com.

Safe Harbor

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other then statements of historical facts, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward- looking statements. The words "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company's forward-looking statements are subject to a number of known and unknown risks and uncertainties that could cause actual results, performance or achievements to differ materially from those described or implied in the forward-looking statements, including, but not limited to, our ability to secure FDA approval for our product candidates under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act; our ability to market, commercialize and achieve market acceptance for product candidates developed using our VIAdel(TM) technology; the progress or success of our research, development and clinical programs, the initiation and completion of our clinical trials, the timing of the interim analyses and the timing or success of our product candidates, particularly VIAject(TM) and VIAtab(TM); our ability to secure patents for VIAject(TM) and our other product candidates; our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others; our estimates of futu
'/>"/>

SOURCE Biodel Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Biodel Inc. to Present VIAject Clinical Progress at the 2007 American Diabetes Association Meeting
2. PromegaExpress Expands Easy Access to Products with New Cabinet
3. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
4. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
5. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
6. Columbia Laboratories Reports Preliminary Findings from the Ongoing Data Analysis of the Phase III Clinical Study of PROCHIEVE 8% (progesterone gel) to Prevent Preterm Birth
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 On Thursday, ... 0.52%, the Dow Jones Industrial Average finished the day 0.42% ... down 0.41%. The losses were broad based as eight out ... 500 Health Care Sector Index ended the day at 711.88, ... last one month. Investor-Edge has initiated coverage on the following ...
(Date:7/11/2014)... 2014 Neurelis, Inc. ("Neurelis") today announced an ... option held by Biotie to purchase Neurelis, clearing the ... (intranasal diazepam) for pediatric and adult epilepsy patients who ... year, Biotie has advanced the development program for NRL-1 ... clinical work required for NDA submission to the FDA.  ...
(Date:7/10/2014)... Integrated Silicon Solution, Inc. (Nasdaq: ... IC solutions, today announced that it will host its ... 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) to ... third quarter ended June 30, 2014. To ... 6:50 a.m. Pacific time on July 24, 2014.  The ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
... Nov. 15, 2011 Reportlinker.com announces that ... in its catalogue: ... India & China ... emerging economies represent a combined pharmaceutical market ...
... Pa, Nov. 15, 2011 As any purchasing manager knows, ... shipping options is time lost. When purchasing surgical instruments ... In January of 2010, Robert Edelstein, President of Millennium ... Saints Charities seeking a vendor for eye surgical instruments ...
Cached Medicine Technology:The Outlook for Pharmaceuticals in Brazil, Russia, India & China 2The Outlook for Pharmaceuticals in Brazil, Russia, India & China 3The Outlook for Pharmaceuticals in Brazil, Russia, India & China 4The Outlook for Pharmaceuticals in Brazil, Russia, India & China 5Millennium Surgical Corp. Provides Instruments to Latter Day Saints Charities for Humanitarian Projects 2
(Date:7/12/2014)... “After my mom’s stroke, she loss the use ... loss the use of his left side. Eating became a difficult ... help people like them enjoy eating again,” said an inventor, from ... PATRICIA CAROL HALL PLATE (P C H PLATE). , The PATRICIA ... way to eat for individuals who suffer from stroke, experience tremors ...
(Date:7/12/2014)... With prom shopping reaching its final days, VogueQueen.com, a ... showcase its new and trendy apparels. Recently, the company ... its online shop. Additionally, it is now providing huge ... According to the company’s sales manager, the promotion will ... , He says, “Now, worldwide clients can order cheap ...
(Date:7/12/2014)... 2014 “Critical Care Therapeutics in ... Late-Stage Four-Factor PCCs and Recombinant Products to Drive ... care market in the US, UK, France, Germany, ... an estimation of market size for 2013, along ... care indications that are being treated using the ...
(Date:7/12/2014)... 2014 Utah Valley Entrepreneurial Forum Top ... awards being bestowed to companies in revenue, and pre-revenue ... community with recognition for new ideas as well as ... revenue. , 25 Under 5 highlights outstanding Utah entrepreneurs ... under 5 years old. Award recipients were recognized at ...
(Date:7/12/2014)... 12, 2014 Praeclarus Press ... as a valuable new resource for women in need ... American women work away from their children. Today’s mothers ... benefits of breastfeeding, but often feel unsupported when it ... babies. With its evidence-based insights, and written by Nancy ...
Breaking Medicine News(10 mins):Health News:VogueQueen.com Updates Its Summer Collection With New And Trendy Evening Dresses 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:SquareHook is Recognized for UVEF 25 Businesses Under 5 Years-Watch Out 2Health News:Praeclarus Press Announces the Release of Working and Breastfeeding Made Simple by Nancy Mohrbacher, A Much Needed Resource For Today's Working Mothers 2
... with highest levels are more apt to have joint replacement, ... of a certain protein strongly predict the risk of hip ... a new study shows. , The research involved 912 healthy ... led to a knee or hip replacement between 1990 and ...
... /PRNewswire/ - rL Solutions, the leading provider of healthcare ... be sponsoring the 2009 MITSS HOPE Award. MITSS and ... 8th Annual Dinner and Fundraiser on Thursday, November 12, ... MITSS established this award in 2008 to recognize people ...
... , , , ... Francisco SPCA ( www.sfspca.org ), the city,s leading privately supported, ... and safety. , , Whether traveling out of ... The SF/SPCA offers this guide for quick and easy reference: ...
... , , , , ... On Tuesday, Governor Schwarzenegger line-item vetoed the Department of Public Health,s ... domestic violence shelters and centers. , , ... advocacy, assistance with restraining orders, counseling and other vital support services. ...
... R.I., July 30 CVS/pharmacy, the nation,s largest retail pharmacy, announced ... with visual impairments and other disabilities. The Company has installed ... website in 2009. , , ... , Today,s announcement is the result of a ...
... patients (three male and seven female) with hepatic angiomyolipoma, ... 19-78 years). Of these patients, dynamic contrast CT showed ... density, absence of a capsule, and prominent central vessels ... with or without a fat component in four cases ...
Cached Medicine News:Health News:Biomarker Could Predict Severe Osteoarthritis 2Health News:rL Solutions to Sponsor 2009 MITSS HOPE Award 2Health News:The San Francisco SPCA Launches Online Guide for Summer Pet Health & Safety 2Health News:The San Francisco SPCA Launches Online Guide for Summer Pet Health & Safety 3Health News:Governor Eliminates Funding to Domestic Violence Programs 2Health News:CVS/pharmacy Enhancing Accessibility for the Visually Impaired To Its Web Site and Store Point of Sales Devices 2Health News:CVS/pharmacy Enhancing Accessibility for the Visually Impaired To Its Web Site and Store Point of Sales Devices 3Health News:CVS/pharmacy Enhancing Accessibility for the Visually Impaired To Its Web Site and Store Point of Sales Devices 4
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
... The Wet-Field Coagulator provides precise episcleral, ... peripheral tissue trauma. Controlled Rf diathermy ... comprehensive line of bipolar Eraser instruments, ... enhanced features that ensure a high ...
Medicine Products: